title: Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?
authors: Department of Dermatology, Allergology and Phlebology, Klinikum Bremerhaven Reinkenheide, Bremerhaven, Germany.
authors: Michael Max
authors: MM
authors: Sachse
authors: Klaus
authors: K
authors: Fenchel
authors: Gunnar
authors: G
authors: Wagner
mesh_terms: D017255:Acitretin / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D017024:Chemotherapy, Adjuvant; D065426:Cytoreduction Surgical Procedures; D005141:Eyelid Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007636:Keratoacanthoma / Q000139:chemically induced* / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008207:Lymphatic Metastasis; D048369:MAP Kinase Kinase 1 / Q000187:drug effects*; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary*; D009367:Neoplasm Staging; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000187:drug effects*; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D048369:MAP Kinase Kinase 1; D017255:Acitretin